EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

东部肿瘤合作组 - 威斯康星州研究

• 批准号: 8465828
• 负责人: Brad Kahl
• 金额: $ 49.69万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8465828
• 关键词: Affect; Basic Science; Cancer Burden; Categories; Clinical; Clinical Research; Clinical Trials; Commit; Comprehensive Cancer Center; Data Quality; Early Diagnosis; Eastern Cooperative Oncology Group; Evaluation; Faculty; Grant; Human; Individual; Institution; Leadership; Malignant Neoplasms; Outcome; Participant; Patients; Population; Prevention; Research; System; Translational Research; Translations; Universities; War; Wisconsin; anticancer research; cancer care; cancer therapy; design; improved; programs

DESCRIPTION (provided by applicant): This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the UW Paul P. Carbone Comprehensive Cancer Center (UWCCC). Over the past 30 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative, and scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC commitment to cancer care and research has never been stronger. During the current grant cycle, we have tripled our clinical space and doubled our research space, representing an institutional commitment of nearly $100 million, and increased our cancer focused faculty by nearly 50%. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. ECOG provides this vital forum and the UWCCC remains highly committed to its mutually beneficial partnership with ECOG.

描述（由申请人提供）：本申请寻求对UW Paul P. Carbone综合癌症中心（UWCCC）东部肿瘤协作组（ECOG）活动的支持。在过去的30年里，UWCCC一直保持着模范的主要机构收益和强大的附属机构参与，同时提供高质量的数据和关键的科学领导。机构评估一致排名华盛顿大学ECOG计划在或接近顶部的类别的应计，行政和科学的领导。UWCCC的基础，转化和临床研究计划旨在通过改善癌症的预防，早期发现和治疗来减少癌症对人口的负担。UWCCC对癌症护理和研究的承诺从未如此强大。在目前的赠款周期，我们已经增加了三倍，我们的临床空间和一倍，我们的研究空间，代表了近1亿美元的机构承诺，并增加了近50%，我们的癌症为重点的教师。UWCCC教师认为NCI合作团体是抗癌战争的重要组成部分。将科学发现转化为人类群体和个体患者需要及时进行大规模临床试验的能力。西非经共体提供了这一重要论坛，UWCCC仍然高度致力于与西非经共体的互利伙伴关系。

项目成果

Potential role of polyribonucleotides in human neoplastic diseases.

多核糖核苷酸在人类肿瘤疾病中的潜在作用。

• 发表时间: 1985
• 期刊: Journal of biological response modifiers
• 作者: Borden,EC;Verma,AK;Wolberg,WH
• 通讯作者: Wolberg,WH

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.

amonafide、caracemide 和高三尖杉酯碱治疗晚期肾细胞癌患者的 II 期试验。

• DOI: 10.1007/bf00180819
• 发表时间: 1996
• 期刊: Investigational new drugs
• 影响因子: 3.4
• 作者: Witte,RS;Hsieh,P;Elson,P;Oken,MM;Trump,DL
• 通讯作者: Trump,DL

Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.

阿霉素和紫杉醇加粒细胞集落刺激因子治疗转移性乳腺癌的 II 期试验：东部肿瘤合作组研究。

• DOI: 10.1200/jco.1999.17.12.3828
• 发表时间: 1999
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: Sparano,JA;Hu,P;Rao,RM;Falkson,CI;Wolff,AC;Wood,WC
• 通讯作者: Wood,WC

Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms.

依托泊苷和极高剂量顺铂：晚期生殖细胞肿瘤患者的挽救治疗。

• 发表时间: 1985
• 期刊: Cancer treatment reports
• 作者: Trump,DL;Hortvet,L
• 通讯作者: Hortvet,L

Phase II trials of interferons-alpha and -beta in advanced sarcomas.

干扰素-α和干扰素-β治疗晚期肉瘤的 II 期试验。

• DOI: 10.1089/jir.1992.12.455
• 发表时间: 1992
• 期刊: Journal of interferon research
• 作者: Borden,EC;Kim,K;Ryan,L;Blum,RH;Shiraki,M;Tormey,DC;Comis,RL;Hahn,RG;Parkinson,DR
• 通讯作者: Parkinson,DR